Aker BioMarine AS
AKBM.OL · OSL
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.03 | -0.15 | -2.20 |
| FCF Yield | -1.01% | -0.48% | -9.12% | -14.92% |
| EV / EBITDA | 17.74 | 15.37 | 8.55 | 14.41 |
| Quality | ||||
| ROIC | -1.92% | 0.18% | 2.37% | 0.89% |
| Gross Margin | 34.72% | 33.67% | 41.41% | 33.60% |
| Cash Conversion Ratio | 0.07 | -5.27 | 1.51 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.46% | 8.56% | -1.33% | 2.11% |
| Free Cash Flow Growth | -173.68% | 93.87% | 61.43% | -7.53% |
| Safety | ||||
| Net Debt / EBITDA | 3.62 | 7.40 | 4.40 | 5.32 |
| Interest Coverage | -2.60 | 0.16 | 1.09 | 0.43 |
| Efficiency | ||||
| Inventory Turnover | 1.35 | 1.21 | 0.89 | 1.26 |
| Cash Conversion Cycle | 311.54 | 314.79 | 401.84 | 306.94 |